Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer

Prostate

Volumn 73, Issue 8, 2013, Pages 813-826

  Chen, Chun Liang ^a   Mahalingam, Devalingam ^b   Osmulski, Pawel ^a   Jadhav, Rohit R ^a   Wang, Chiou Miin ^a   Leach, Robin J ^b   Chang, Tien Cheng ^b   Weitman, Steven D ^b,c   Kumar, Addanki Pratap ^b   Sun, Luzhe ^b   Gaczynska, Maria E ^a   Thompson, Ian M ^b   Huang, Tim Hui Ming ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c CTRC Institute for Drug Development   (United States)

Author keywords

circulating tumor cells; metastasis; prostate cancer

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; AURORA A KINASE; AXL RECEPTOR TYROSINE KINASE; CD45 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPITHELIAL CELL ADHESION MOLECULE; GLI FAMILY ZINC FINGER 3; HEPATOCYTE NUCLEAR FACTOR 3BETA; MUCIN 1; OSTEOGENIC PROTEIN 1; OSTEOPONTIN; PIM 2 PROTEIN; PIM 3 PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEIN; PROTEIN KINASE PIM 1; PROTEIN PATCHED 1; PROTEIN PATCHED 2; SMAD2 PROTEIN; SOMATOMEDIN B; SOMATOMEDIN C; SONIC HEDGEHOG PROTEIN; TRANSCRIPTION FACTOR FOXC2; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA1; TRANSFORMING GROWTH FACTOR BETA2; TRANSFORMING GROWTH FACTOR BETA3; UNCLASSIFIED DRUG; UNINDEXED DRUG; WNT5A PROTEIN;

ADULT; AGED; ARTICLE; ATOMIC FORCE MICROSCOPY; CANCER INVASION; CASTRATION RESISTANT PROSTATE CANCER; CELL MEMBRANE; CIRCULATING TUMOR CELL; CIRCULATION; CLINICAL ARTICLE; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIOID CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; METASTASIS; MICROFILTRATION; MICROFLUIDICS; MICROMANIPULATION; PREDICTION; PRIORITY JOURNAL; SINGLE CELL ANALYSIS;

CELL LINE, TUMOR; DNA, NEOPLASM; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MICROFLUIDIC ANALYTICAL TECHNIQUES; MICROSCOPY, ATOMIC FORCE; NEOPLASMS, HORMONE-DEPENDENT; NEOPLASTIC CELLS, CIRCULATING; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SINGLE-CELL ANALYSIS;

EID: 84876948946     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22625     Document Type: Article

References (38)

1. Aguirre-Ghiso JA,. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007; 7: 834-846.
2. Meng S, Tripathy D, Frenkel EP, Shete S, Naftalis EZ, Huth JF, Beitsch PD, Leitch M, Hoover S, Euhus D, Haley B, Morrison L, Fleming TP, Herlyn D, Terstappen LW, Fehm T, Tucker TF, Lane N, Wang J, Uhr JW,. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res 2004; 10: 8152-8162.
3. Dittmar T, Heyder C, Gloria-Maercker E, Hatzmann W, Zanker KS,. Adhesion molecules and chemokines: The navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis 2008; 25: 11-32.
4. Sun YX, Schneider A, Jung Y, Wang J, Dai J, Cook K, Osman NI, Koh-Paige AJ, Shim H, Pienta KJ, Keller ET, McCauley LK, Taichman RS,. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20: 318-329.
5. Alix-Panabieres C, Schwarzenbach H, Pantel K,. Circulating tumor cells and circulating tumor DNA. Annu Rev Med 2012; 63: 199-215.
6. Danila DC, Heller G, Gignac GA, Gonzalez-Espinoza R, Anand A, Tanaka E, Lilja H, Schwartz L, Larson S, Fleisher M, Scher HI,. Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res 2007; 13: 7053-7058.
7. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW,. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004; 10: 6897-6904.
8. Helo P, Cronin AM, Danila DC, Wenske S, Gonzalez-Espinoza R, Anand A, Koscuiszka M, Vaananen RM, Pettersson K, Chun FK, Steuber T, Huland H, Guillonneau BD, Eastham JA, Scardino PT, Fleisher M, Scher HI, Lilja H,. Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: Concordance with CellSearch assay and association with bone metastases and with survival. Clin Chem 2009; 55: 765-773.
9. Scher HI, Jia X, de Bono JS, Fleisher M, Pienta KJ, Raghavan D, Heller G,. Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: A reanalysis of IMMC38 trial data. Lancet Oncol 2009; 10: 233-239.
10. de Bono JS, Scher HI, Montgomery RB, Parker C, Miller MC, Tissing H, Doyle GV, Terstappen LW, Pienta KJ, Raghavan D,. Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res 2008; 14: 6302-6309.
11. Goodman OB Jr, Fink LM, Symanowski JT, Wong B, Grobaski B, Pomerantz D, Ma Y, Ward DC, Vogelzang NJ,. Circulating tumor cells in patients with castration-resistant prostate cancer baseline values and correlation with prognostic factors. Cancer Epidemiol Biomarkers Prev 2009; 18: 1904-1913.
12. Coumans FA, Doggen CJ, Attard G, de Bono JS, Terstappen LW,. All circulating EpCAM + CK + CD45- objects predict overall survival in castration-resistant prostate cancer. Ann Oncol 2010; 21: 1851-1857.
13. Danila DC, Pantel K, Fleisher M, Scher HI,. Circulating tumors cells as biomarkers: Progress toward biomarker qualification. Cancer J 2011; 17: 438-450.
14. Yu M, Stott S, Toner M, Maheswaran S, Haber DA,. Circulating tumor cells: Approaches to isolation and characterization. J Cell Biol 2011; 192: 373-382.
15. Taylor RA, Toivanen R, Risbridger GP,. Stem cells in prostate cancer: Treating the root of the problem. Endocr Relat Cancer 2010; 17: R273-R285.
16. Kalluri R, Weinberg RA,. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
17. Doyen J, Alix-Panabieres C, Hofman P, Parks SK, Chamorey E, Naman H, Hannoun-Levi JM,. Circulating tumor cells in prostate cancer: A potential surrogate marker of survival. Crit Rev Oncol Hematol 2012; 81: 241-256.
18. Danila DC, Fleisher M, Scher HI,. Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res 2011; 17: 3903-3912.
19. Desitter I, Guerrouahen BS, Benali-Furet N, Wechsler J, Janne PA, Kuang Y, Yanagita M, Wang L, Berkowitz JA, Distel RJ, Cayre YE,. A new device for rapid isolation by size and characterization of rare circulating tumor cells. Anticancer Res 2011; 31: 427-441.
20. Citri A, Pang ZP, Sudhof TC, Wernig M, Malenka RC,. Comprehensive qPCR profiling of gene expression in single neuronal cells. Nat Protoc 2012; 7: 118-127.
21. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-408.
22. Popovici V, Goldstein DR, Antonov J, Jaggi R, Delorenzi M, Wirapati P,. Selecting control genes for RT-QPCR using public microarray data. BMC Bioinformatics 2009; 10: 42.
23. Powell AA, Talasaz AH, Zhang H, Coram MA, Reddy A, Deng G, Telli ML, Advani RH, Carlson RW, Mollick JA, Sheth S, Kurian AW, Ford JM, Stockdale FE, Quake SR, Pease RF, Mindrinos MN, Bhanot G, Dairkee SH, Davis RW, Jeffrey SS,. Single cell profiling of circulating tumor cells: Transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS ONE 2012; 7: e33788.
24. Gautier L, Cope L, Bolstad BM, Irizarry RA,. Affy-analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004; 20: 307-315.
25. Cross SE, Jin YS, Rao J, Gimzewski JK,. Nanomechanical analysis of cells from cancer patients. Nat Nanotechnol 2007; 2: 780-783.
26. Faria EC, Ma N, Gazi E, Gardner P, Brown M, Clarke NW, Snook RD,. Measurement of elastic properties of prostate cancer cells using AFM. Analyst 2008; 133: 1498-1500.
27. Lekka M, Pogoda K, Gostek J, Klymenko O, Prauzner-Bechcicki S, Wiltowska-Zuber J, Jaczewska J, Lekki J, Stachura Z,. Cancer cell recognition-Mechanical phenotype. Micron 2012; 43: 1259-1266.
28. Girasole M, Pompeo G, Cricenti A, Congiu-Castellano A, Andreola F, Serafino A, Frazer BH, Boumis G, Amiconi G,. Roughness of the plasma membrane as an independent morphological parameter to study RBCs: A quantitative atomic force microscopy investigation. Biochim Biophys Acta 2007; 1768: 1268-1276.
29. Chen DT, Weeks ER, Crocker JC, Islam MF, Verma R, Gruber J, Levine AJ, Lubensky TC, Yodh AG,. Rheological microscopy: Local mechanical properties from microrheology. Phys Rev Lett 2003; 90: 108301.
30. Wang J, Wan Z, Liu W, Li L, Ren L, Wang X, Sun P, Zhao H, Tu Q, Zhang Z, Song N, Zhang L,. Atomic force microscope study of tumor cell membranes following treatment with anti-cancer drugs. Biosens Bioelectron 2009; 25: 721-727.
31. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH,. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22: 2790-2799.
32. Nauseef JT, Henry MD,. Epithelial-to-mesenchymal transition in prostate cancer: Paradigm or puzzle ? Nat Rev Urol 2011; 8: 428-439.
33. Gupta S, Iljin K, Sara H, Mpindi JP, Mirtti T, Vainio P, Rantala J, Alanen K, Nees M, Kallioniemi O,. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2010; 70: 6735-6745.
34. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF,. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363: 411-422.
35. Darshan MS, Loftus MS, Thadani-Mulero M, Levy BP, Escuin D, Zhou XK, Gjyrezi A, Chanel-Vos C, Shen R, Tagawa ST, Bander NH, Nanus DM, Giannakakou P,. Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011; 71: 6019-6029.
36. Jiang Y, Palma JF, Agus DB, Wang Y, Gross ME,. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem 2010; 56: 1492-1495.
37. Zhu ML, Kyprianou N,. Role of androgens and the androgen receptor in epithelial-mesenchymal transition and invasion of prostate cancer cells. FASEB J 2010; 24: 769-777.
38. Sun Y, Wang BE, Leong KG, Yue P, Li L, Jhunjhunwala S, Chen D, Seo K, Modrusan Z, Gao WQ, Settleman J, Johnson L,. Androgen deprivation causes epithelial-mesenchymal transition in the prostate: Implications for androgen-deprivation therapy. Cancer Res 2012; 72: 527-536.